Salven P - Search Results

1

Serum vascular endothelial growth factor is often elevated in disseminated cancer.

Salven P, Mänpää H, Orpana A, Alitalo K, Joensuu H. Salven P, et al. Clin Cancer Res. 1997 May;3(5):647-51. Clin Cancer Res. 1997. PMID: 9815732

2

Angiogenic and lymphangiogenic molecules in hematological malignancies.

Orpana A, Salven P. Orpana A, et al. Among authors: salven p. Leuk Lymphoma. 2002 Feb;43(2):219-24. doi: 10.1080/10428190290005964. Leuk Lymphoma. 2002. PMID: 11999550 Review.

3

High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer.

Ruotsalainen T, Joensuu H, Mattson K, Salven P. Ruotsalainen T, et al. Among authors: salven p. Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1492-5. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12433733 Clinical Trial.

4

Endothelial Tie growth factor receptor provides antigenic marker for assessment of breast cancer angiogenesis.

Salvén P, Joensuu H, Heikkilä P, Matikainen MT, Wasenius VM, Alanko A, Alitalo K. Salvén P, et al. Br J Cancer. 1996 Jul;74(1):69-72. doi: 10.1038/bjc.1996.317. Br J Cancer. 1996. PMID: 8679461 Free PMC article.

5

Enhanced expression of vascular endothelial growth factor in metastatic melanoma.

Salven P, Heikkilä P, Joensuu H. Salven P, et al. Br J Cancer. 1997;76(7):930-4. doi: 10.1038/bjc.1997.486. Br J Cancer. 1997. PMID: 9328154 Free PMC article.

6

A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma.

Salven P, Teerenhovi L, Joensuu H. Salven P, et al. Blood. 1997 Oct 15;90(8):3167-72. Blood. 1997. PMID: 9376599 Free article.

7

Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance.

Salven P, Heikkilä P, Anttonen A, Kajanti M, Joensuu H. Salven P, et al. Mod Pathol. 1997 Nov;10(11):1128-33. Mod Pathol. 1997. PMID: 9388064

8

Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3.

Jussila L, Valtola R, Partanen TA, Salven P, Heikkilä P, Matikainen MT, Renkonen R, Kaipainen A, Detmar M, Tschachler E, Alitalo R, Alitalo K. Jussila L, et al. Among authors: salven p. Cancer Res. 1998 Apr 15;58(8):1599-604. Cancer Res. 1998. PMID: 9563467

9

High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer.

Salven P, Ruotsalainen T, Mattson K, Joensuu H. Salven P, et al. Int J Cancer. 1998 Apr 17;79(2):144-6. doi: 10.1002/(sici)1097-0215(19980417)79:2<144::aid-ijc8>3.0.co;2-t. Int J Cancer. 1998. PMID: 9583728 Clinical Trial.

10

Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.

Salven P, Lymboussaki A, Heikkilä P, Jääskela-Saari H, Enholm B, Aase K, von Euler G, Eriksson U, Alitalo K, Joensuu H. Salven P, et al. Am J Pathol. 1998 Jul;153(1):103-8. doi: 10.1016/S0002-9440(10)65550-2. Am J Pathol. 1998. PMID: 9665470 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters